Across TCGA pan-cancer cohorts, ALKBH2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ALKBH2 data layer compared with 25 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher ALKBH2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ALKBH2 expression acts as an unfavorable survival marker, although some lineages such as LSCC and UCEC show a favorable association.

LSCC, UCEC, and GBM are the cancer types where ALKBH2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	OS	Tertile	II,III,IV	1.000	0.574	.004	32	view →
UCEC	OS	Median	II,III,IV	1.000	0.647	.017	8	view →
GBM	DFS	Quartile	All	0.450	0.224	.010	8	view →
HNSC	DFS	Median	III,IV	0.396	0.778	.004	5	view →
LUAD	OS	Median	III,IV	0.408	0.879	.040	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: ALKBH2 tumor-vs-normal RNA expression · all ALKBH2 data types